Advertisement

 

 

Development and identification of a new Vero cell-based live attenuated influenza B vaccine by a modified classical reassortment method.

Development and identification of a new Vero cell-based live attenuated influenza B vaccine by a modified classical reassortment method.
Author Information (click to view)

Yang F, Ma L, Zhou J, Wu Y, Gao J, Song S, Geng X, Guo Q, Li Z, Li W, Liao G, Li Y,


Yang F, Ma L, Zhou J, Wu Y, Gao J, Song S, Geng X, Guo Q, Li Z, Li W, Liao G, Li Y, (click to view)

Yang F, Ma L, Zhou J, Wu Y, Gao J, Song S, Geng X, Guo Q, Li Z, Li W, Liao G, Li Y,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of vaccines 2017 07 14() 1-9 doi 10.1080/14760584.2017.1337514

Abstract
BACKGROUND
It was to generate a new Vero and cold-adapted live attenuated influenza B vaccine with enough safety and immunogenicity.

METHODS
According to modified classical reassortment method, the donor strain was B/Yunnan/2/2005Vca(B), and the parental virus strain was B/Brisbane/60/2008wt. After co-infection in Vero cells, the prepared antibody serum inhibited the donor strain growth, and screening conditions inhibited the parental virus growth, which induced the growth of the new reassortant virus B/Brisbane/60/2008Vca(B) grow. Through intraperitoneal injection (i.j.) and intranasal injection (n.j.) we evaluated the safety and immunogenicity of the vaccine.

RESULTS
A high-yield of the reassortant virus was produced in Vero cells at 25°C, similar to the donor strains. After sequencing, it was found that B/Brisbane/60/2008Vca(B) Hemagglutinin (HA) and Neuraminidase (NA) gene fragments were from B/Brisbane/60/2008wt, while the other 6 gene fragments were from B/Yunnan/2/2005Vca(B). The n.j. immune pathway experiments showed no significant differences between the treatment and the PBS control group with respect to weight changes (P > 0.5). Furthermore, the new strain had a sufficient geometric mean titter (GMT) against B/Brisbane/60/2008wt.

CONCLUSION
The new reassortant live attenuated influenza B vaccine was safe and having enough immune stimulating ability.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × 3 =

[ HIDE/SHOW ]